These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 11720431

  • 21. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.
    Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, Pillay M, Nooter K, Stoter G, Verweij J.
    Cancer Res; 1999 Apr 01; 59(7):1454-7. PubMed ID: 10197613
    [Abstract] [Full Text] [Related]

  • 22. Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL.
    Ellis AG, Webster LK.
    Cancer Chemother Pharmacol; 1999 Apr 01; 43(1):13-8. PubMed ID: 9923536
    [Abstract] [Full Text] [Related]

  • 23. Disposition kinetics of taxanes after intraperitoneal administration in rats and influence of surfactant vehicles.
    Yokogawa K, Jin M, Furui N, Yamazaki M, Yoshihara H, Nomura M, Furukawa H, Ishizaki J, Fushida S, Miwa K, Miyamoto K.
    J Pharm Pharmacol; 2004 May 01; 56(5):629-34. PubMed ID: 15142340
    [Abstract] [Full Text] [Related]

  • 24. Delayed seizure associated with paclitaxel-Cremophor el in a patient with early-stage breast cancer.
    O'Connor TL, Kossoff E.
    Pharmacotherapy; 2009 Aug 01; 29(8):993-6. PubMed ID: 19637953
    [Abstract] [Full Text] [Related]

  • 25. Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.
    Gelderblom H, Verweij J, van Zomeren DM, Buijs D, Ouwens L, Nooter K, Stoter G, Sparreboom A.
    Clin Cancer Res; 2002 Apr 01; 8(4):1237-41. PubMed ID: 11948138
    [Abstract] [Full Text] [Related]

  • 26. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.
    Liu J, Kraut EH, Balcerzak S, Grever M, D'Ambrosio S, Chan KK.
    Cancer Chemother Pharmacol; 2002 Dec 01; 50(6):445-53. PubMed ID: 12451470
    [Abstract] [Full Text] [Related]

  • 27. Surfactants influence the distribution of taxanes in peritoneal dissemination tumor-bearing rats.
    Kamijo Y, Ito C, Nomura M, Sai Y, Miyamoto K.
    Cancer Lett; 2010 Jan 28; 287(2):182-6. PubMed ID: 19608331
    [Abstract] [Full Text] [Related]

  • 28. Phase I trial of cremophor EL with bolus doxorubicin.
    Millward MJ, Webster LK, Rischin D, Stokes KH, Toner GC, Bishop JF, Olver IN, Linahan BM, Linsenmeyer ME, Woodcock DM.
    Clin Cancer Res; 1998 Oct 28; 4(10):2321-9. PubMed ID: 9796961
    [Abstract] [Full Text] [Related]

  • 29. Pharmacokinetics and neutrophil toxicity of paclitaxel orally administered in mice with recombinant interleukin-2.
    Jamois C, Comets E, Mentré F, Marion S, Farinotti R, Bonhomme-Faivre L.
    Cancer Chemother Pharmacol; 2005 Jan 28; 55(1):61-71. PubMed ID: 15378273
    [Abstract] [Full Text] [Related]

  • 30. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A.
    van Asperen J, van Tellingen O, van der Valk MA, Rozenhart M, Beijnen JH.
    Clin Cancer Res; 1998 Oct 28; 4(10):2293-7. PubMed ID: 9796957
    [Abstract] [Full Text] [Related]

  • 31. Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats.
    Park JH, Park JH, Hur HJ, Woo JS, Lee HJ.
    Eur J Pharm Sci; 2012 Feb 14; 45(3):296-301. PubMed ID: 22172604
    [Abstract] [Full Text] [Related]

  • 32. Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.
    Sparreboom A, Verweij J, van der Burg ME, Loos WJ, Brouwer E, Viganò L, Locatelli A, de Vos AI, Nooter K, Stoter G, Gianni L.
    Clin Cancer Res; 1998 Aug 14; 4(8):1937-42. PubMed ID: 9717822
    [Abstract] [Full Text] [Related]

  • 33. Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.
    Lockhart AC, Bukowski R, Rothenberg ML, Wang KK, Cooper W, Grover J, Appleman L, Mayer PR, Shapiro M, Zhu AX.
    Cancer Chemother Pharmacol; 2007 Jul 14; 60(2):203-9. PubMed ID: 17091249
    [Abstract] [Full Text] [Related]

  • 34. Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours.
    Veltkamp SA, Rosing H, Huitema AD, Fetell MR, Nol A, Beijnen JH, Schellens JH.
    Cancer Chemother Pharmacol; 2007 Oct 14; 60(5):635-42. PubMed ID: 17205304
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients.
    Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, Jusko WJ.
    Cancer Chemother Pharmacol; 2009 May 14; 63(6):1035-48. PubMed ID: 18791717
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Effect of dimethyl sulfoxide on bladder tissue penetration of intravesical paclitaxel.
    Chen D, Song D, Wientjes MG, Au JL.
    Clin Cancer Res; 2003 Jan 14; 9(1):363-9. PubMed ID: 12538489
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.